Reducing opioid analgesic deaths in America: What health providers can do

Pain Physician

Volumn 18, Issue 3, 2015, Pages E307-E322

  Agarin, Taghogho ^a   Trescot, Andrea ^b   Agarin, Aniefiok ^c   Lesanics, Doreena ^d   Decastro, Claricio ^d  

^a University of California at San Diego   (United States)

^b Algone Pain Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Columbia University ^*  (United States)

Author keywords

Genetic testing for opioids; Methadone deaths; Opioid analgesic deaths; Opioid guidelines; Opioid mortality; Urine drug testing

Indexed keywords

BUPRENORPHINE; CARBAMAZEPINE; CLONIDINE; GABAPENTIN; METHADONE; MIRTAZAPINE; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG; VALPROIC ACID; ANALGESIC AGENT;

ARTICLE; AWARENESS; CHRONIC PAIN; DEATH; DRUG MONITORING; DRUG OVERDOSE; DRUG SCREENING; GENETIC SCREENING; HEALTH CARE PERSONNEL; HUMAN; OPIOID ANALGESIC DEATH; PAIN ASSESSMENT; PATIENT MONITORING; PATIENT RISK; RISK ASSESSMENT; EPIDEMIOLOGY; MORTALITY; PAIN; PROCEDURES; STANDARDS; SUBSTANCE ABUSE; UNITED STATES;

ANALGESICS; ANALGESICS, OPIOID; CHRONIC PAIN; DRUG OVERDOSE; HEALTH PERSONNEL; HUMANS; PAIN; SUBSTANCE ABUSE DETECTION; UNITED STATES;

EID: 84929471973     PISSN: 15333159     EISSN: 21501149     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Prescription Drug Overdose in the United States: Fact Sheet Centers for Disease Control and Prevention, Available at www.cdc.gov/homeandrecreationalsafety/ overdose/facts.html Accessed on April 9, 2015.
2. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - guidance. Pain Physician 2012; 15:S67-S116.
3. Hall AJ, logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixter D, Crosby AE, Paulozzi LJ. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300:2613-2620.
4. Model policy for the use of controlled substances for the treatment of pain. Federation of State Medical Boards of the United States. Available at www.fsmb.org/pdf/2004_grpol_Controlled_ Substances.pdf. Accessed April 9, 2015.
5. HR.2260- Pain Relief Promotion Act of 2000. Available at beta.congress.gov/ bill/106th-congress/house-bill/2260. Accessed April 9, 2015.
6. H.R. 1863 (108th): National Pain Care Policy Act of 2003 108th Congress, 2003-2004. Available at www.govtrack.us/congress/bills/108/hr1863/text Accessed August 23, 2014.
7. Lippe PM. The decade of pain control and research. Pain Med 2000; 1:286.
8. Public law 111–148. Patient Protection and Affordable Care Act. 2010. Available at: http://gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf Accessed December, 23, 2012.
9. CDC. Policy impact: Prescription painkiller overdoses. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at: www.cdc.gov/drugoverdose/pdf/policyimpact-prescriptionpainkillerod-a.pdf Accessed April 9,2015.
10. Centers for Disease Control and Prevention. February 22/29, 2012. CDC Grand Rounds: Prescription drug overdoses - A US epidemic. JAMA 2012; 307:774-776.
11. Modesto-Lowe V, Brooks D, Petry N. Methadone deaths: Risk factors in pain and addicted populations. J Gen Intern Med 2010; 25:305-309.
12. Srivasatava A, Kahan M. Methadone induction doses: Are our current practices safe? J Addict Dis 2006; 25:5-13. doi: 10.1300/J069v25n03_02.
13. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ. Opioid prescriptions for chronic pain and overdose: A cohort study. Annals of Internal Medicine 2010; 152:85-92.
14. Bohnert AS, Valenstein M, Bair MJ, McCarthy JF, Ganoczy D, Iigen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305:1315-1321.
15. Reisfield GM, Salazar EL, Bertholf RL. Rational Use and Interpretation of Urine Drug Testing in Chronic Opioid Therapy. Annals of Clinical and Laboratory Science,. 2007; 37:301-314
16. Adams NJ, Plane MB, Fleming MF, Mundt MP, Saunders LA, Stauffacher EA. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage 2001; 22:791-796.
17. Gasche Y, Youssef D, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351:27.
18. U.S. Food and Drug Administration: FDA Reminds the Public about the Potential for Life-Threatening Harm from Accidental Exposure to Fentanyl Transdermal Systems (“Patches”). Available at http://www.fda.gov/Drugs/DrugSafety/ucm300747.htm Accessed April 9, 2015.
19. Lanier WA, Johnson EM, Rolf RT, Freidrichs L, Grey TC. Risk factors for prescription opioid-related death, Utah, 2008-2009. Pain Med 2012; 13:1580-1589. doi: 10.1111/j.1526-4637.2012.01518.x. Epub 2012 Nov 8.
20. Johnson EM, Lanier WA, Merril RM, Crook J, Porucznik CA, Rolfs RT, Sauer BJ. Unintentional prescription opioidrelated overdose deaths: Description of decedents by next of kin or best contact, Utah, 2008-2009. J Gen Intern Med. 2013; 28:522-529
21. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends in Pharmacological Sciences 2001; 22:67-70.
22. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity 2012; 13:562-570.
23. Von Korff MR. Opioids for chronic noncancer pain: As the pendulum swings, who should set prescribing standards for primary care? Ann Fam Med 2012; 10:302-303.
24. McKitrick C. Youth’s overdose sends strong message. Salt Lake City Tribune 2011 May 17. Available at www.sltrib. com/sltrib/news/51689248-78/prescription- drugs-drug-watson.html.csp Accessed April 9, 2015.
25. Backman M. Hernando investigators say 2-year-old girl died after taking mom’s oxycodone. Tampa Bay Times July 12, 2011 need date} www.tampabay.com/news/hernando-investigatorssay-2-year-old-girl-died-after-takingmoms-oxycodone/1180084 Accessed April 9, 2015.
26. Field J. Report: State prescription monitoring programs falling short. Maine Broadcasting Network.September.2012 www.mpbn.net/News/MPBNNews/tabid/1159/ctl/ViewItem/mid/3762/ItemId/23843/Default.aspx Accessed April 9, 2015.
27. Walker JM, Farney RJ, Rhondeau SM, Boyle KM, Valentine K, Cloward TV, Shilling KC. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007;3:455-461.
28. Farney RJ, Walker JM, Cloward TV, Rhondeau S. Sleep-disordered breathing associated with long term opioid therapy. Chest 2003; 123:632-639.
29. Wang D, Teichtahl H, Drummer O, Goodman C, Cherry G, Cunnington D, Kronborg L. Central sleep apnea in stable methadone maintenance treatment patients. Chest 2005; 128:1348-56.
30. Wu PC, Lang C, Hasson NK, Linder SH, Clark DJ. Opioid use in young veterans. J Opioid Manag 2010; 6:133-139.
31. Volkow, ND, McLellan TA, Cotto JH, Karithanom M, Weiss SRB. Characteristics of opioid prescriptions in 2009. JAMA 2011; 305:1299-1301. doi:10.1001/jama.2011.401
32. Alam A, Gomes T, Zheng H, Mandani M, Juurlink DN, Bell CM. Long-term analgesic use after low-risk surgery: A retrospective cohort study. Arch Intern Med 2012; 172:425.
33. Sullivan MD, Ballantyne JC. What are we treating with long-term opioid therapy? Arch Intern Med 2012; 172:433-434.
34. Sjogren P, Gronbak M, Peuckmann V, Ekholm O. A population-based cohort study on chronic pain: The role of opioids. Clin J Pain 2010; 26:763-769.
35. Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An Educational Aid to Improve Care and Safety with Opioid Therapy 2010 Update. Available at: www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf
36. Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: Psychiatric disorders and chronic pain. Neurotherapeutics 2007; 4:75-83.
37. Salehi M, Kheirabadi GR, Maracy MR, Ranjkesh M. Importance of gabapentin dose in treatment of opioid withdrawal. Journal of Clinical Psychopharmacology 2001; 31:593-596.
38. Verduin ML, McKay S, Verduin ML, McKay S, Brady KT. Gabapentin in comorbid anxiety and substance use. American Journal on Addictions 2007; 16:142-143.
39. Martınez-Raga J, Sabater A, Perez- Galvez B, Castellano M, Cervera G. Add-on gabapentin in the treatment of opiate withdrawal. Progress in Neuro- Psychopharmacology and Biological Psychiatry 2004; 28:599-601.
40. Kumar P, Jain MK. Gabapentin in the management of pentazocine dependence: A potent analgesic-anticraving agent. J Assoc Physicians India 2003; 51:673-676.
41. Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of gabapentinlike compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl) 2001; 157:381-387.
42. Gustorff B, Kozek-Langenecker S, Kress HG. Gabapentin: The first preemptive antihyperalgesic for opioid withdrawal hyperalgesia? Anesthesiology 2003; 98:1520-1521.
43. Kheirabadi, GR, Ranjkesh M, Maracy MR, Salehi M. Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction 2008; 103:1495-1499.
44. Graves, SM, Rafeyan R, Watts J, Napier TC. Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: Evidence from the bench and the bedside. Pharmacology and Therapeutics 2012; 136:343-353.
45. Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Higgins ST. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 2013; 70:1347-1354.
46. Weiss, RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin, J, Griffin ML, Gourevitch MN, Haller DL, Huang Z, Jacobs P, Kosinski A.S, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W. Adjunctive counseling during brief and extended bupenorphine- naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry 2001; 68:1238-1246.
47. Heit HA, Gourlay DL. Tackling the difficult problem of prescription opioid misuse. Annals of Intern Med 2010; 152: 747-748.
48. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 2010; 152:712-720. doi:10.7326/0003-4819
49. Cheatle MD, Savage SR. Informed consent in opioid therapy: A potential obligation and opportunity. Journal Pain Symptom Management 2012; 44:105-116.
50. Hegmann KT, Weiss MS, Bowden K, Branco F, DuBrueler K, Els C, Mandel, S, McKinney DW, Miguel R, Mueller KL, Nadig R, Schaffer MI, Studt L, Talmage J, Travis RL, Winters T, Thiese MS, Harris J. ACOEM Practice Guidelines: Opioids for Treatment of Acute, Subacute, Chronic, and Postoperative Pain. J Occupational and Environmental Medicine 2014; 56:e143–e159.
51. Jones T, Moore T, Levy J, Daffron JL, Browder S, Allen JH, Passik L, Steven D. A comparison of various risk screening methods in predicting discharge from opioid treatment. The Clinical Journal of Pain 2012; 28:93-100.
52. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: A review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician 2012; 15:ES67-ES92.
53. Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, Colson J. Urine drug testing in chronic pain. Pain Physician 2011; 14:123-143.
54. Atluri S, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic noncancer pain: an algorithmic, evidence based approach. Pain Physician 2012; 15:ES177-ES189.
55. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non- Cancer Pain 2010. Available at: http://nationalpaincentre.mcmaster.ca/opioid/ Accessed April 9, 2015.
56. Smith HS. Opioid metabolism. Mayo Clin Proc 2009;84:613-624.
57. Heit HA, Gourlay DL. Urine drug testing in pain medicine. Journal of Pain and Symptom Management 2004; 27: 260-267.
58. Keary CJ, Wang Y, Moran JR, Zayas LV, Stem TA. Toxicologic testing for opiates: Understanding false-positive and falsenegative test results. Prim Care Companion CNS Disord 2012; 14PCC.12f01371. Published online Jul 26, 2012. doi: 10.4088/PCC.12f01371
59. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clinical Pharmacology and Therapeutics 2008; 4:559-566.
60. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty Acta Anaesthesiologica Sacndinavica 2006; 50:787-792.
61. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006; 16:625-636.
62. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005; 14:135-143.
63. FDA Drug Safety Communication: Safety review update of codeine use in children; new boxed warning and contraindication on use after tonsillectomy and/ or adenoidectomy. August, 2012. Available at www.fda.gov/Drugs/DrugSafety/ucm339112.htm Accessed April 9, 2015.
64. Trescot AM, Faynboym S. A review of the role of genetic testing in pain medicine. Pain Physician 2014; 17: 425-445.
65. The National Alliance for Model State Drug Laws (NAMSDL). Status of State Drug Prescription Monitoring Programs, December 13, 2014. Available at: www.namsdl.org/library/6D4C4D9F-65BE-F4BB-A428B392538E0663/ Accessed April 9, 2015.
66. Worley J. Prescription drug monitoring programs, a response to doctor shopping: Purpose, effectiveness, and directions for future research. Issues in Mental Health Nursing 2012; 33:319-328.
67. Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, Bucher Bartelson B. Do prescription monitoring programs impact state trends in opioid abuse/ misuse? Pain Medicine 2012; 13:434–442. doi: 10.1111/j.1526-4637.2012.01327.
68. Warning Access Data FDA-Food and Drug administration. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2010/022272lbl.pdf Accessed April 9, 2015.
69. Jumbelic M. Death with fentanyl transdermal patches. The American Journal of Forensic Medicine and Pathology 2010; 31:18-21.
70. Lake Erie Medical DBA Quality Care Products LLC OXYCONTIN - oxycodone hydrochloride tablet http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=42277 accessed April 9, 2015.
71. Caplehorn JRM. Deaths in the first two weeks of maintenance treatment in NSW. Drug and Alcohol Review 1998; 17: 9-17:
72. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved. Med J Aust 1999; 170:104-109.
73. Gomes T, Mamdani MM, Dhalla IA, Paterson MJ, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011; 171:686-691. doi:10.1001/archinternmed2011
74. Franklin G, Mai J, Turner J, Sullivan M, Wickizier T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: Impact of the Washington State opioid dosing guideline. American Journal of Industrial Medicine 2012; 55:325-331.
75. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends in Pharmacological Sciences 2001; 22: {need pages}
76. Fine PG, Portenoy RK. Establishing “best practices” for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage 2009; 38:418-425.
77. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study. Cancer 1998; 82:1167-1173.
78. Foley KM, Houde RW. Methadone in cancer pain management: Individualize dose and titrate to effect. Journal of Clinical Oncology 1988; 16:3213-3215.
79. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Medicine 2008; 9:315–344. doi: 10.1111/j.1526-4637.2006.00289.x
80. Vital signs: Risks for overdose from methadone used for pain relief - United States, 1999-2000. Centers for Disease Control and Prevention; Mortality and Morbidity Weekly Report 2012; 61:493-497.
81. The College of Physicians and Surgeons of Ontario. Methadone for pain guidelines 2004. Available at: www.scribd.com/ doc/102866/Methadone-Pain-Management-Physicians-guidelines-Ontario-Canada Accessed April 9, 2015.
82. Goodman WN, Jones WN, Glassman P. Methadone dosing recommendations for treatment of chronic pain. Available at www.pbm.va.gov/clinicalguidance/clinicalrecommendations/Methadone-DosingRecommendations.pdf Accessed April 9, 2015.
83. Crettol S, Déglon JJ, Besson J, Croquette- Krokar M, Hämmig R, Gothuey I, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clinical Pharmacology and Therapeutics 2006; 80:668-681.
84. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clinical Pharmacology and Therapeutics 1987; 41:392-401.
85. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone. Clinical Pharmacokinetics 2002; 41:1153-1193.
86. Holmstrand J, Anggård E, Gunne LM. Methadone maintenance: Plasma levels and therapeutic outcome. Clinical Pharmacology and Therapeutics 1978; 23:175-180.
87. Tagliaro F, Battisti ZD, Smith FP, Marigo M. Death from heroin overdose: Findings from hair analysis. The Lancet 1998; 351:1923-1925.
88. Farrell M, Marsden J. Acute risk of drugrelated death among newly released prisoners in England and Wales. Addiction 2008; 103:251-255.
89. Dahler D, Hirschkorn P. Nose spray narcan reverses overdoses in Mass. town at high rate. CBS News July 21, 2013. Available at www.cbsnews.com/news/nosespray-narcan-reverses-overdoses-inmass-town-at-high-rate/ Accessed April 9 2014.
90. Slevin KA, Ashburn MA. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag 2011; 7:109-115.
91. Siegal HA, Carlson RG, Keene PR, Swora MG. Probable relationship between opioid abuse and heroin use Am Fam Physician 2003; 67:942-945.
92. Collin, J. Minnesota Heroin Addicts Hooked Via Prescription Opiates. MPR News: Minessota Public Radio Feb 28, 2012. Available at http://minnesota.publicradio.org/display/web/2012/02/28/prescription-opiates-a-gateway-to-heroin-especially-in-minnesota Accessed April 9, 2015.
93. Golberg D, Quelly J. Heroin use among young in NJ is up and in more suburban areas. Star Ledger Oct 7, 2012. Available at www.nj.com/news/index.ssf/2012/10/heroin_use_among_young_in_nj_i.html Accessed April 9,2015.
94. Rector K. Ocean City dealing with overwhelming increase in heroin cases. The Baltimore Sun, Dec 04, 2012. Available at http://articles.baltimoresun.com/2012-12-04/news/bs-md-oceancity-bust-20121204_1_heroin-cases-heroin- abuse-drug-arrests Accessed April 9, 2015.
95. Farney J. Regulation of prescription drugs could spell trouble for patients. Metro Focus, June 15, 2012. Available at: www.thirteen.org/metrofocus/2012/06/regulation-of-prescription-drugscould-spell-trouble-for-patients/ Accessed April 9, 2015.
96. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O’Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C. Clinical guidelines for the use of chronic opioid therapy in chronic non cancer pain. The Journal of Pain 2009; 10:113-130.
97. Opioids for persistent pain: summary of guidance on good practice from the British Pain Society. British Journal of Pain 2012; 6:9-10.
98. Gnanadesigan N, Espinoza RT, Smith R, Isreal M, Reuben DB. Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected? J Am Med Dir Assoc 2005; 6:265-269.
99. Bailey AM, Wermeling DP. Naloxone for opioid overdose prevention: Pharmacists’ role in community-based practice settings. Ann Pharmacother. 2014; 48:601- 606. doi: 10.1177/1060028014523730. Epub 2014 Feb 12.